Dermatology Services

News

WINTER 2017


ECZEMA BREAKTHROUGH

The FDA has approved Dupilumab for the treatment of adults who have inadequately controlled eczema with topical therapies.

The medicine is injected under the skin. The Dupilumab binds to a protein called IL-4 that causes inflammation and inhibits the inflammatory response. The medicine appears very effective in clinical trials. Trial participants got excellent responses and reduction of itch. There were some side effects with allergic reactions and eye inflammation being the most serious.

This is very exciting news for patients with difficult atopic dermatitis. Let's hope it becomes available in New Zealand soon.